Carisma Therapeutics, Inc. (CARM)
NASDAQ: CARM · Real-Time Price · USD
0.862
-0.005 (-0.54%)
Nov 20, 2024, 4:00 PM EST - Market open

Carisma Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
20.2714.929.83--
Revenue Growth (YoY)
41.13%51.71%---
Cost of Revenue
63.5174.1356.6234.39-
Gross Profit
-43.24-59.21-46.78-34.39-
Selling, General & Admin
23.5329.539.386.415.09
Research & Development
----23.29
Operating Expenses
23.5329.539.386.4128.38
Operating Income
-66.77-88.73-56.16-40.79-28.38
Interest Expense
---3.15--
Interest & Investment Income
2.781.94-0.010.03
Other Non Operating Income (Expenses)
--0.08-1.92--
Pretax Income
-64-86.88-61.23-40.78-28.35
Net Income
-63.8-86.88-61.23-40.78-28.35
Net Income to Common
-63.8-86.88-61.23-40.78-28.35
Shares Outstanding (Basic)
4134211
Shares Outstanding (Diluted)
4134211
Shares Change (YoY)
71.70%1475.33%96.30%1.95%-
EPS (Basic)
-1.55-2.59-28.77-37.62-26.66
EPS (Diluted)
-1.55-2.59-28.77-37.62-26.66
Free Cash Flow
-68.35-82.31-9.78-39.2-27.45
Free Cash Flow Per Share
-1.66-2.46-4.59-36.16-25.82
Operating Margin
-329.46%-594.75%-571.10%--
Profit Margin
-314.78%-582.34%-622.60%--
Free Cash Flow Margin
-337.21%-551.71%-99.41%--
EBITDA
-63.37-85.89-54.27-40.11-27.93
D&A For EBITDA
3.412.841.890.680.45
EBIT
-66.77-88.73-56.16-40.79-28.38
Source: S&P Capital IQ. Standard template. Financial Sources.